Ependymoma overview: Difference between revisions
No edit summary |
|||
| (7 intermediate revisions by 4 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Ependymoma''' is the third most common neuroepithelial tumor of the [[central nervous system]] (CNS) in childhood. It arises for ependymal cells of the central nervous system and is dominated by [[intracranial mass]]. The World Health Organization (WHO) classification of CNS tumors defines several [[histopathological]] variants of ependymoma ( | '''Ependymoma''' is the third most common neuroepithelial tumor of the [[central nervous system]] (CNS) in childhood. It arises for ependymal cells of the central nervous system and is dominated by [[intracranial mass]]. The World Health Organization (WHO) classification of CNS tumors defines several [[histopathological]] variants of ependymoma (grade I, II, III). On [[gross pathology]], a well-encapsulated [[tumor]] arises from the floor of the [[fourth ventricle]], situated in the lower back portion of the [[brain]] is a characteristic finding of ependymoma. On [[microscopic]] histopathological analysis, perivascular pseudorosettes are characteristic findings of ependymoma. Development of ependymoma is the result of multiple genetic mutations (''ERBB2'', ''ERBB4'', ''[[MMP2]]'', ''MMP14'', ''[[NOTCH1]]'', and ''[[MEN1]]''). There are no established causes for ependymomas. Ependymoma must be differentiated from [[medulloblastoma]], [[choroid plexus papilloma]], and [[glioblastoma]]. Common risk factors in the development of ependymoma are children with certain hereditary diseases ([[neurofibromatosis]] type II and Turcot syndrome), ''ERBB2'', ''ERBB4'', and human telomerase reverse transcriptase ''TERT'' gene expression, over-expression of [[kinetochore]] proteins, and down-regulation of [[metallothionein|metallothioneins]].Symptoms of ependymoma include [[headache]], [[nausea]], [[vomiting]], blurry or [[double vision]], [[drowsiness]] (after several hours of the above symptoms), [[irritability]], [[ataxia]], neck pain, [[cranial nerve palsies]], [[seizures]], [[focal neurologic deficits]], [[back pain]], lower extremity weakness, bowel and bladder dysfunction. MRI may be diagnostic of ependymoma. Finding on brain MRI suggestive of ependymoma include large mixed cystic/solid lesion with [[haemorrhage]] and [[fluid]] which may indicate areas of [[necrosis]]. The predominant therapy for ependymoma is surgical resection. Adjunctive chemoradiation may be required. | ||
==Classification== | ==Classification== | ||
Ependymoma may be classified into several subtypes based on [[WHO]] classification ( | Ependymoma may be classified into several subtypes based on [[WHO]] classification (grade I, II, III) and the site of origin. | ||
==Pathology== | ==Pathology== | ||
On [[gross pathology]], a well-encapsulated [[tumor]] arises from the floor of the [[fourth ventricle]], situated in the lower back portion of the [[brain]] is a characteristic finding of ependymoma. On [[microscopic]] histopathological analysis, perivascular pseudorosettes are characteristic findings of ependymoma. Development of ependymoma is the result of multiple genetic mutations (''ERBB2'', ''ERBB4'', ''[[MMP2]]'', ''MMP14'', ''[[NOTCH1]]'', and ''[[MEN1]]''). | On [[gross pathology]], a well-encapsulated [[tumor]] arises from the floor of the [[fourth ventricle]], situated in the lower back portion of the [[brain]] is a characteristic finding of ependymoma. On [[microscopic]] histopathological analysis, perivascular pseudorosettes are characteristic findings of ependymoma. Development of ependymoma is the result of multiple genetic mutations (''ERBB2'', ''ERBB4'', ''[[MMP2]]'', ''MMP14'', ''[[NOTCH1]]'', and ''[[MEN1]]''). | ||
==Causes== | ==Causes== | ||
There are no established causes for ependymomas. | There are no established causes for ependymomas. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
The incidence of ependymoma is approximately 0.05 to 0.08 per 100,000 individuals in the United States.<ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/publications/pdq</ref>The posterior fossa tumours tend to present more commonly in the paediatric age group (mean age at diagnosis is 6 years of age)Men and women are affected equally by ependymomal tumors | The incidence of ependymoma is approximately 0.05 to 0.08 per 100,000 individuals in the United States.<ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/publications/pdq</ref>The posterior fossa tumours tend to present more commonly in the paediatric age group (mean age at diagnosis is 6 years of age). Men and women are affected equally by ependymomal tumors. | ||
==Risk Factors== | ==Risk Factors== | ||
Common risk factors in the development of ependymoma are children with certain hereditary diseases ([[neurofibromatosis]] type II and Turcot syndrome) | Common risk factors in the development of ependymoma are children with certain hereditary diseases ([[neurofibromatosis]] type II and Turcot syndrome), over-expression of [[kinetochore]] proteins, and down-regulation of [[metallothionein|metallothioneins]]. | ||
==Differentiating Ependymoma from other Diseases== | ==Differentiating Ependymoma from other Diseases== | ||
Ependymoma must be differentiated from [[medulloblastoma]], [[choroid plexus papilloma]], and [[glioblastoma]]. | Ependymoma must be differentiated from [[medulloblastoma]], [[choroid plexus papilloma]], and [[glioblastoma]]. | ||
| Line 35: | Line 38: | ||
Brain MRI may be diagnostic of ependymoma. Finding on brain MRI suggestive of ependymoma include large mixed cystic/solid lesion with [[haemorrhage]] and [[fluid]] which may indicate areas of [[necrosis]]. | Brain MRI may be diagnostic of ependymoma. Finding on brain MRI suggestive of ependymoma include large mixed cystic/solid lesion with [[haemorrhage]] and [[fluid]] which may indicate areas of [[necrosis]]. | ||
===Ultrasound=== | ===Ultrasound=== | ||
Intraoperative ultrasound is used in intradural spinal ependymomas. | Intraoperative ultrasound is used in intradural spinal ependymomas. | ||
===Other Diagnostic Studies=== | ===Other Diagnostic Studies=== | ||
Other diagnostic studies for ependymoma include [[EEG]], which demonstrates various abnormalities, and [[cerebrospinal fluid]] analysis, which demonstrates positive [[cytology]]. | Other diagnostic studies for ependymoma include [[EEG]], which demonstrates various abnormalities, and [[cerebrospinal fluid]] analysis, which demonstrates positive [[cytology]]. | ||
==Treatment== | ==Treatment== | ||
===Medical Therapy=== | ===Medical Therapy=== | ||
| Line 46: | Line 49: | ||
There are no primary preventive measures available for ependymoma. | There are no primary preventive measures available for ependymoma. | ||
===Secondary Prevention=== | ===Secondary Prevention=== | ||
Secondary prevention strategies following ependymoma include regular clinical assessment and [[neuroimaging]]. | Secondary prevention strategies following ependymoma include regular clinical assessment and [[neuroimaging]]. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
| Line 55: | Line 58: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Latest revision as of 18:31, 26 September 2019
|
Ependymoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ependymoma overview On the Web |
|
American Roentgen Ray Society Images of Ependymoma overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]
Overview
Ependymoma is the third most common neuroepithelial tumor of the central nervous system (CNS) in childhood. It arises for ependymal cells of the central nervous system and is dominated by intracranial mass. The World Health Organization (WHO) classification of CNS tumors defines several histopathological variants of ependymoma (grade I, II, III). On gross pathology, a well-encapsulated tumor arises from the floor of the fourth ventricle, situated in the lower back portion of the brain is a characteristic finding of ependymoma. On microscopic histopathological analysis, perivascular pseudorosettes are characteristic findings of ependymoma. Development of ependymoma is the result of multiple genetic mutations (ERBB2, ERBB4, MMP2, MMP14, NOTCH1, and MEN1). There are no established causes for ependymomas. Ependymoma must be differentiated from medulloblastoma, choroid plexus papilloma, and glioblastoma. Common risk factors in the development of ependymoma are children with certain hereditary diseases (neurofibromatosis type II and Turcot syndrome), ERBB2, ERBB4, and human telomerase reverse transcriptase TERT gene expression, over-expression of kinetochore proteins, and down-regulation of metallothioneins.Symptoms of ependymoma include headache, nausea, vomiting, blurry or double vision, drowsiness (after several hours of the above symptoms), irritability, ataxia, neck pain, cranial nerve palsies, seizures, focal neurologic deficits, back pain, lower extremity weakness, bowel and bladder dysfunction. MRI may be diagnostic of ependymoma. Finding on brain MRI suggestive of ependymoma include large mixed cystic/solid lesion with haemorrhage and fluid which may indicate areas of necrosis. The predominant therapy for ependymoma is surgical resection. Adjunctive chemoradiation may be required.
Classification
Ependymoma may be classified into several subtypes based on WHO classification (grade I, II, III) and the site of origin.
Pathology
On gross pathology, a well-encapsulated tumor arises from the floor of the fourth ventricle, situated in the lower back portion of the brain is a characteristic finding of ependymoma. On microscopic histopathological analysis, perivascular pseudorosettes are characteristic findings of ependymoma. Development of ependymoma is the result of multiple genetic mutations (ERBB2, ERBB4, MMP2, MMP14, NOTCH1, and MEN1).
Causes
There are no established causes for ependymomas.
Epidemiology and Demographics
The incidence of ependymoma is approximately 0.05 to 0.08 per 100,000 individuals in the United States.[1]The posterior fossa tumours tend to present more commonly in the paediatric age group (mean age at diagnosis is 6 years of age). Men and women are affected equally by ependymomal tumors.
Risk Factors
Common risk factors in the development of ependymoma are children with certain hereditary diseases (neurofibromatosis type II and Turcot syndrome), over-expression of kinetochore proteins, and down-regulation of metallothioneins.
Differentiating Ependymoma from other Diseases
Ependymoma must be differentiated from medulloblastoma, choroid plexus papilloma, and glioblastoma.
Natural History, Complication and Prognosis
If left untreated, patients with ependymoma may progress to develop nausea, vomiting, headache, and irritability. Common complications of ependymoma include seizure, hydrocephalus, muscle paralysis, and speech problems.
Diagnosis
History and Symptoms
Symptoms of ependymoma include headache, nausea, and irritability.
Physical Examination
Patients with ependymoma usually appear well. Physical examination of patients with ependymoma is usually remarkable for altered mental status, spasticity, and muscle weakness.
Staging
There is no established system for the staging of ependymoma.
Laboratory Findings
There are no diagnostic lab findings associated with ependymoma.
CT
Head CT scan may be diagnostic of ependymoma. Findings on CT scan suggestive of ependymoma include heterogeneous mass with coarse calcification, solid component, and cystic component.
MRI
Brain MRI may be diagnostic of ependymoma. Finding on brain MRI suggestive of ependymoma include large mixed cystic/solid lesion with haemorrhage and fluid which may indicate areas of necrosis.
Ultrasound
Intraoperative ultrasound is used in intradural spinal ependymomas.
Other Diagnostic Studies
Other diagnostic studies for ependymoma include EEG, which demonstrates various abnormalities, and cerebrospinal fluid analysis, which demonstrates positive cytology.
Treatment
Medical Therapy
The predominant therapy for ependymoma is surgical resection. Adjunctive chemoradiation may be required.
Surgery
Surgery is the main stay of treatment for myxopapillary ependymoma (WHO grade 1), subependymoma (WHO grade 1), ependymoma (WHO grade I), and anaplastic ependymoma (WHO grade III).
Primary Prevention
There are no primary preventive measures available for ependymoma.
Secondary Prevention
Secondary prevention strategies following ependymoma include regular clinical assessment and neuroimaging.
References
- ↑ National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/publications/pdq